Potassium in CKD: Friend or Foe?
作者信息
Turban Sharon, Gudino Paola, Melamed Michal L
机构信息
Division of Nephrology, Johns Hopkins School of Medicine, Baltimore, Maryland.
Department of Medicine, Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, New York.
出版信息
Kidney360. 2024 Dec 1;5(12):1785-1787. doi: 10.34067/KID.0000000658.
Abstract
摘要
相似文献
1
Potassium in CKD: Friend or Foe?
Kidney360. 2024 Dec 1;5(12):1785-1787. doi: 10.34067/KID.0000000658.
2
[Microbial "friend-foe" identification in human intestine microsymbiocenosis].
Zh Mikrobiol Epidemiol Immunobiol. 2011 Nov-Dec(6):46-51.
3
The Aryl Hydrocarbon Receptor in Chronic Kidney Disease: Friend or Foe?
Front Cell Dev Biol. 2020 Dec 7;8:589752. doi: 10.3389/fcell.2020.589752. eCollection 2020.
4
The role of statins in chronic kidney disease (CKD): friend or foe?
Pharmacol Ther. 2009 Jun;122(3):312-23. doi: 10.1016/j.pharmthera.2009.03.008. Epub 2009 Apr 5.
5
FRIEND or FOE: A prospective evaluation of risk factors for reintubation in surgical and trauma patients.
Am J Surg. 2018 Dec;216(6):1056-1062. doi: 10.1016/j.amjsurg.2018.07.004. Epub 2018 Jul 10.
6
The role of FGF-23 in CKD-MBD and cardiovascular disease: friend or foe?
Nephrol Dial Transplant. 2010 May;25(5):1376-81. doi: 10.1093/ndt/gfp784. Epub 2010 Feb 2.
7
Apolipoprotein L1 Genotypes and the Association of Urinary Potassium Excretion with CKD Progression.
Clin J Am Soc Nephrol. 2022 Oct;17(10):1477-1486. doi: 10.2215/CJN.02680322. Epub 2022 Aug 31.
8
Novel Potassium Binders in Reduction of Hyperkalemia and Optimization of RAAS Inhibitors Treatment in Patients with Chronic Kidney Disease or Heart Failure: A Systematic Review and Meta-analysis.
Drugs. 2025 Jun 21. doi: 10.1007/s40265-025-02198-6.
9
Estimated potassium intake and the progression of chronic kidney disease.
Nephrol Dial Transplant. 2024 Nov 27. doi: 10.1093/ndt/gfae277.
10
Interplay between chronic kidney disease (CKD) and upper tract urothelial carcinomas (UUC): foe or friend?
Oncotarget. 2016 Aug 16;7(33):53951-53958. doi: 10.18632/oncotarget.9753.
本文引用的文献
1
Hyperkalemia and Risk of CKD Progression: A Propensity Score-Matched Analysis.
Kidney360. 2024 Dec 1;5(12):1824-1834. doi: 10.34067/KID.0000000000000541. Epub 2024 Aug 9.
2
Long-term Patiromer Use and Outcomes Among US Veterans With Hyperkalemia and CKD: A Propensity-Matched Cohort Study.
Kidney Med. 2023 Nov 27;6(1):100757. doi: 10.1016/j.xkme.2023.100757. eCollection 2024 Jan.
3
Hyperkalemia in Chronic Kidney Disease: Links, Risks and Management.
Int J Nephrol Renovasc Dis. 2022 Aug 2;15:215-228. doi: 10.2147/IJNRD.S326464. eCollection 2022.
4
Hyperkalemia-Related Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in CKD: A Population-Based Cohort Study.
Am J Kidney Dis. 2022 Aug;80(2):164-173.e1. doi: 10.1053/j.ajkd.2022.01.002. Epub 2022 Jan 25.
5
A multiple 24-hour urine collection study indicates that kidney function decline is related to urinary sodium and potassium excretion in patients with chronic kidney disease.
Kidney Int. 2022 Jan;101(1):164-173. doi: 10.1016/j.kint.2021.10.030. Epub 2021 Nov 11.
6
Dietary Potassium Intake and Risk of Chronic Kidney Disease Progression in Predialysis Patients with Chronic Kidney Disease: A Systematic Review.
Adv Nutr. 2020 Jul 1;11(4):1002-1015. doi: 10.1093/advances/nmaa027.
7
Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis.
Eur Heart J. 2018 May 1;39(17):1535-1542. doi: 10.1093/eurheartj/ehy100.
8
The frequency of hyperkalemia and its significance in chronic kidney disease.
Arch Intern Med. 2009 Jun 22;169(12):1156-62. doi: 10.1001/archinternmed.2009.132.
Zotero 插件